Biomarkers in Multiple Sclerosis: Tracking Disease Progression

In this episode of MD Newsline, Dr. Ahmed Abdelhak, Assistant Professor of Neurology at the University of California, San Francisco, explores the cutting-edge world of fluid biomarkers in multiple sclerosis (MS). With over a decade of experience as an MS clinical scientist, Dr. Abdelhak shares his expertise on the evolving role of biomarkers in understanding, predicting, and managing MS progression. He breaks down how markers like neurofilament light chain (NFL), glial fibrillary acidic protein (GFAP), and chitinase (CHIT1/CHIT3) offer insights into the underlying neuroinflammatory and neurodegenerative processes in MS. From identifying axonal damage to detecting astrocyte activation and microglial involvement, these biomarkers are transforming how clinicians assess disease activity and progression risk. Dr. Abdelhak also discusses the potential of machine learning and AI-based models in interpreting complex, multi-center datasets — paving the way for personalized treatment strategies. He emphasizes the importance of cross-specialty collaboration, incorporating radiology, immunology, and physical therapy, to deliver holistic MS care that addresses both neurological and everyday challenges faced by patients. Episode Highlights Advancements in MS Biomarkers Dr. Abdelhak reviews emerging biomarkers — including GFAP and chitinases — and explains their cellular origins, from astrocytes to microglia, offering a multidimensional view of disease mechanisms. Clinical Value of GFAP and NFL He explains how GFAP reflects astrocyte activation and correlates with disease progression, while NFL indicates axonal damage. Combining both markers enables a more precise prediction of MS activity and long-term disability outcomes. Machine Learning and Data Integration AI is reshaping MS research by harmonizing large, noisy datasets and uncovering biologically meaningful clusters of patients. This integration of fluid, imaging, and genetic data supports early identification of disease subtypes and better treatment matching. Personalized and Holistic MS Management Dr. Abdelhak underscores the future of individualized biomarker trajectories, which could guide treatment adjustments and predict therapy response. He also highlights the need for patient advocacy, encouraging individuals to voice concerns about cognitive symptoms, fatigue, and depression often overlooked in clinical settings. The Path Ahead for MS Research He anticipates major breakthroughs in the next five years, especially in identifying new biomarker panels and understanding under-researched pathways involving astrocytes and microglia. Collaboration across specialties and clearer communication with patients will be crucial to translating these scientific insights into daily clinical care. Key Takeaway Dr. Ahmed Abdelhak emphasizes that fluid biomarkers are redefining MS care — enabling earlier, more accurate detection of disease progression and treatment response. The integration of AI tools, multi-omics data, and cross-specialty collaboration is driving a new era of precision medicine in neurology, offering patients more informed and individualized care pathways. Resources Website: https://mdnewsline.com/ Newsletter: https://mdnewsline.com/subscribe/ Connect with Dr. Ahmed Abdelhak: Here